Business Context and Reporting Period
This Form 8-K, filed on July 24, 2002, reports E. I. du Pont de Nemours and Company's (DuPont) financial results for the second quarter ended June 30, 2002. The filing includes an earnings news release and consolidated financial statements. The reporting period reflects the adoption of SFAS No. 142, which eliminated goodwill amortization but required a one-time cumulative effect charge for goodwill impairment.
Key Financial Metrics
- Revenue: Consolidated sales were $6.7 billion for the quarter, a 4% decrease from $7.0 billion in the prior year. Segment sales were $7.4 billion, down 5% year-over-year, though up 1% on a comparable business basis due to a 5% volume increase offset by a 4% price decline.
- Profitability: Reported net income was $543 million ($0.54 per share), compared to a net loss of $213 million ($0.21 per share) in the second quarter of 2001. Underlying earnings (excluding one-time items) were $0.71 per share, a 73% increase from $0.41 per share in the prior year.
- Cash Flow and Liquidity: The filing text does not provide specific operating cash flow or liquidity ratios for the quarter. However, the company noted the early extinguishment of $242 million in debentures, incurring a $21 million charge.
- Margins: After-tax operating income (ATOI) before one-time items increased 45% to $853 million, driven by lower raw material and fixed costs.
- Debt: Specific total debt figures are not provided in the text, though the company actively managed its capital structure through share repurchases (reducing shares by 4%) and debt extinguishment.
Material Changes Versus Prior Period
- Accounting Change: A significant noncash charge of $2.9 billion ($2.94 per share) was recorded in the year-to-date results for the cumulative effect of adopting SFAS No. 142 regarding goodwill impairment. This charge turned year-to-date earnings into a loss of $1.93 per share, despite underlying profitability.
- One-Time Items: The current quarter included a net charge of $0.17 per share from one-time items, primarily a $209 million restructuring charge in the Textiles & Interiors segment. This contrasts with the prior year quarter, which had a net charge of $0.62 per share.
- Segment Performance:
- Performance Materials: ATOI surged 163% due to higher volumes and lower raw material costs.
- Textiles & Interiors: ATOI improved dramatically to $91 million from $7 million, aided by cost reductions and higher capacity utilization.
- Electronic & Communication Technologies: Sales and ATOI declined 6% and 16%, respectively, due to weak market conditions and price pressure.
Guidance, Outlook, and Risks
- Outlook: Management expects the global economic recovery to continue, led by North America and Asia, with a slower recovery in Europe. Economic conditions in South America remain uncertain.
- Earnings Guidance: DuPont expects third-quarter 2002 underlying earnings per share to be approximately double those of the third quarter of 2001. Fourth-quarter 2002 underlying earnings are expected to be about triple those of the fourth quarter of 2001.
- Risks and Contingencies:
- Potential negative impact on second-half revenues from political/economic uncertainties in South America.
- Continued pricing pressure in certain segments, though management believes the environment has stabilized.
- Forward-looking statements are subject to risks including changes in laws, regulations, competitive pressures, and raw material costs.
Investor Verification Checklist
- Verify the impact of the $2.9 billion noncash goodwill impairment charge on year-to-date reported losses versus underlying operational performance.
- Confirm the sustainability of the 73% increase in underlying earnings per share, specifically the contribution from lower raw material costs versus volume growth.
- Monitor the execution of the Textiles & Interiors restructuring plan and its effect on future fixed costs.
- Assess the risk exposure to South American economic conditions regarding Agriculture & Nutrition revenues.
- Review the progress of the divestiture of the Clysar shrink films business and the pending sale of the European manufacturing facility in Agriculture & Nutrition.